RT Journal Article
SR Electronic
T1 A baseline transcriptional signature associates with clinical malaria risk in RTS,S/AS01-vaccinated African children
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.19.21257227
DO 10.1101/2021.05.19.21257227
A1 Gemma Moncunill
A1 Jason Carnes
A1 William Chad Young
A1 Lindsay N. Carpp
A1 Stephen De Rosa
A1 Joseph J. Campo
A1 Augusto J. Nhabomba
A1 Maximillian Mpina
A1 Chenjerai Jairoce
A1 Greg Finak
A1 Paige Haas
A1 Carl Murie
A1 Phu Van
A1 Héctor Sanz
A1 Sheetij Dutta
A1 Benjamin Mordmüller
A1 Selidji T. Agnandji
A1 Núria Díez-Padrisa
A1 Nana A. Williams
A1 John J. Aponte
A1 Clarissa Valim
A1 Daniel E. Neafsey
A1 Claudia Daubenberger
A1 Juliana McElrath
A1 Carlota Dobaño
A1 Ken Stuart
A1 Raphael Gottardo
YR 2021
UL http://medrxiv.org/content/early/2021/05/19/2021.05.19.21257227.abstract
AB In a phase 3 trial in African infants/children, the RTS,S/AS01 (GSK) vaccine showed moderate efficacy against clinical malaria. We aimed to identify RTS,S/AS01-induced signatures associated with clinical malaria by analyzing antigen-stimulated peripheral blood mononuclear cells sampled from a subset of trial participants at baseline and month 3 (one month post-third dose). RTS,S/AS01 vaccination was associated with downregulation of B-cell and monocyte-related blood transcriptional modules (BTMs) and upregulation of T-cell related BTMs, as well as higher month 3 (vs baseline) circumsporozoite protein (CSP)-specific CD4+ T-cell responses. There were few RTS,S/AS01-associated BTMs whose month 3 levels correlated with malaria risk. In contrast, baseline levels of BTMs associated with dendritic cells and with monocytes (among others) correlated with malaria risk. A cross-study analysis supported generalizability of the baseline dendritic cell- and monocyte-related BTM correlations with malaria risk to healthy, malaria-naïve adults, suggesting inflammatory monocytes may inhibit protective RTS,S/AS01-induced responses.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT00866619Funding StatementFunding was obtained from the NIH-NIAID (R01AI095789), NIH-NIAID (U19AI128914), PATH Malaria Vaccine Initiative (MVI), Ministerio de Economia y Competitividad (Instituto de Salud Carlos III, PI11/00423 and PI14/01422). The RNA-seq project has been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Grant Number U19AI110818 to the Broad Institute. This study was also supported by the Vaccine Statistical Support (Bill and Melinda Gates Foundation award INV-008576/OPP1154739 to R.G.). C.D. was the recipient of a Ramon y Cajal Contract from the Ministerio de Economia y Competitividad (RYC-2008-02631). G.M. was the recipient of a Sara Borrell-ISCIII fellowship (CD010/00156) and work was performed with the support of Department of Health, Catalan Government grant (SLT006/17/00109). This research is part of the ISGlobal's Program on the Molecular Mechanisms of Malaria which is partially supported by the Fundacion Ramon Areces and we acknowledge support from the Spanish Ministry of Science and Innovation through the "Centro de Excelencia Severo Ochoa 2019-2023" Program (CEX2018-000806-S), and support from the Generalitat de Catalunya through the CERCA Program.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the Ethical Committee of the Hospital Clinic in Barcelona (CEIC, Spain), the National Health and Bioethics Committee (CNBS, Mozambique), the Ethikkommission Beider Basel (EKBB, Switzerland), the National Institutional Review Board (NIMR, Tanzania), the Ifakara Health Institute IRB (IHIIRB, Tanzania), the Lambarene Independent Regional Ethic Committee (CERIL, Gabon) and the Research Ethics Committee (REC, USA). The study teams complied with the Declaration of Helsinki and Good Clinical Practice including monitoring of data. Written informed consent was obtained from the adult volunteers and children's parents or guardians before recruitment.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available from the corresponding authors upon reasonable request.